Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Coronary Artery Disease
Intervention: Regadenoson (Drug); Adenosine (Drug); N-13 ammonia (Drug)
Phase: N/A
Status: Completed
Sponsored by: Mayo Clinic Official(s) and/or principal investigator(s): Panithaya Chareonthaitawee, M.D., Principal Investigator, Affiliation: Mayo Clinic
Summary
Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain),
heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress
myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the
coronary arteries. During the PET MPI test, a drug is given to mimic the effects of exercise
on the heart. The study was done to measure blood flow to the heart using two similar drugs
approved to mimic the effects of exercise on the heart in people during a heart stress test.
The first drug, called adenosine, has been approved for this use for several decades. The
second drug, called regadenoson, was approved in 2008. The investigators were looking at
whether the increase in blood flow to the heart with the newer drug (regadenoson) was
similar to the increase in blood flow with the older drug (adenosine). This information is
important for the use of these drugs in patients and for interpreting the blood flow values.
Clinical Details
Official title: Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Primary outcome: Global Hyperemic Myocardial Blood Flow (MBF)
Secondary outcome: Resting Global MBF and Resting Segmental MBFGlobal Cardiac Flow Rate Hyperemic Segmental MBF Segmental CFR Heart Rate (Beats Per Minute (BPM)) Hyperemic Blood Pressure (mmHg)
Detailed description:
The hypothesis for this study was that Regadenoson will produce a very similar degree of
maximal hyperemia (increased blood flow) as adenosine, the other vasodilator agent. There
were only 2 days on study for each subject.
On Day 1 of the study, subjects were interviewed and had a physical exam, including a
resting 12-lead electrocardiogram (ECG) to exclude evidence of silent ischemia or myocardial
infarction, and other cardiovascular disorders. Subjects were instructed to have a light
meal at least 4 hours prior to the PET MPI. Subjects were instructed to abstain from
caffeine-containing products for 24 hours prior to the PET scan. Day 1 of the study occurred
less than or equal to 4 weeks of Day 2.
On Day 2 of the study, each subject underwent three PET N-13 ammonia (10-20 mCi) dynamic
emission acquisitions: resting, regadenoson (0. 4 mg/5 mL IV), and adenosine (140
microgram/kg/min; order of regadenoson vs adenosine was randomized according to subject's
birth year), and three transmission acquisitions for attenuation correction. Each emission
acquisition was separated by 50 min to allow for radioactive decay. At the end of the drug
infusions, subjects were monitored for 5-30 min. Based on the known short biological
half-lives of these stress agents, the pharmacologic effects of each drug should have
dissipated by the time the next drug was administered.
Eligibility
Minimum age: 30 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy male and female volunteers over the age of 30.
- Written informed consent will be obtained from each subject.
- Each subject will undergo a history and physical examination
Exclusion Criteria:
- Any cardiovascular or pulmonary symptoms or exam findings
- History of low blood pressure (< 90/50 mmHg)
- Prior cardiac history
- History of hypertension
- History of hyperlipidemia
- History of diabetes mellitus
- History of asthma or chronic obstructive pulmonary disease
- Weight of > 450 pounds
- Chronic kidney disease
- Other serious illness such as cancer
- Current smoking
- Medication use (with the exception of acetaminophen, aspirin, nonsteroidal
anti-inflammatory drugs (NSAIDs), and thyroid hormone replacement)
- Illicit drug use
- Prior allergic reaction to adenosine, regadenoson, or aminophylline
- Pregnancy
Locations and Contacts
Mayo Clinic, Rochester, Minnesota 55905, United States
Additional Information
Starting date: February 2011
Last updated: September 3, 2013
|